Winkler, Emma S.

Potently neutralizing and protective human antibodies against SARS-CoV-2

Zost, S. J., Gilchuk, P., Case, J. B., Binshtein, E., Chen, R. E., Nkolola, J. P., Schäfer, A., Reidy, J. X., Trivette, A., Nargi, R. S., et al. (2020) · Nature

SARS-CoV-2 and COVID-19 ResearchMonoclonal and Polyclonal Antibodies Research

Cited by 1,041

SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function

Winkler, E. S., Bailey, A. L., Kafai, N. M., Nair, S., McCune, B. T., Yu, J., Fox, J. M., Chen, R. E., Earnest, J. T., Keeler, S. P., et al. (2020) · Nature Immunology

SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studies

Cited by 901

Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies

Chen, R. E., Zhang, X., Case, J. B., Winkler, E. S., Liu, Y., VanBlargan, L. A., Liu, J., Errico, J. M., Xie, X., Suryadevara, N., et al. (2021) · Nature Medicine

SARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections Studies

Cited by 881

Loss of furin cleavage site attenuates SARS-CoV-2 pathogenesis

Johnson, B. A., Xie, X., Bailey, A. L., Kalveram, B., Lokugamage, K. G., Muruato, A., Zou, J., Zhang, X., Juelich, T., Smith, J. K., et al. (2021) · Nature

SARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections Studies

Cited by 694

Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection

Winkler, E. S., Gilchuk, P., Yu, J., Bailey, A. L., Chen, R. E., Chong, Z., Zost, S. J., Jang, H., Huang, Y., Allen, J. D., et al. (2021) · Cell

SARS-CoV-2 and COVID-19 ResearchMonoclonal and Polyclonal Antibodies Research

Cited by 366

Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein

Suryadevara, N., Shrihari, S., Gilchuk, P., VanBlargan, L. A., Binshtein, E., Zost, S. J., Nargi, R. S., Sutton, R. E., Winkler, E. S., Chen, E. C., et al. (2021) · Cell

SARS-CoV-2 and COVID-19 ResearchMonoclonal and Polyclonal Antibodies Research

Cited by 361

SARS-CoV-2 Infects Human Engineered Heart Tissues and Models COVID-19 Myocarditis

Bailey, A. L., Dmytrenko, O., Greenberg, L., Bredemeyer, A. L., Ma, P., Liu, J., Penna, V., Winkler, E. S., Sviben, S., Brooks, E., et al. (2021) · JACC: Basic to Translational Science

Viral Infections and Immunology ResearchCOVID-19 Clinical Research Studies

Cited by 193

A Potently Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection

Alsoussi, W. B., Turner, J. S., Case, J. B., Zhao, H., Schmitz, A. J., Zhou, J. Q., Chen, R. E., Lei, T., Rizk, A. A., McIntire, K. M., et al. (2020) · The Journal of Immunology

SARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections Studies

Cited by 181

Profiling B cell immunodominance after SARS-CoV-2 infection reveals antibody evolution to non-neutralizing viral targets

Dugan, H. L., Stamper, C. T., Li, L., Changrob, S., Asby, N. W., Halfmann, P. J., Zheng, N.-Y., Huang, M., Shaw, D. G., Cobb, M. S., et al. (2021) · Immunity

SARS-CoV-2 and COVID-19 ResearchT-cell and B-cell Immunology

Cited by 134

Ultrapotent miniproteins targeting the SARS-CoV-2 receptor-binding domain protect against infection and disease

Case, J. B., Chen, R. E., Cao, L., Ying, B., Winkler, E. S., Johnson, M., Goreshnik, I., Pham, M. N., Shrihari, S., Kafai, N. M., et al. (2021) · Cell Host & Microbe

SARS-CoV-2 and COVID-19 Researchvaccines and immunoinformatics approaches

Cited by 73